Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
BostonGene is partnering with NEC and Transgene to continue performing tumor molecular profiling and microenvironment analysis and provide high-throughput sequencing services.
- BostonGene is partnering with NEC and Transgene to continue performing tumor molecular profiling and microenvironment analysis and provide high-throughput sequencing services.
- The partnership with BostonGene will enable fast turnaround of next-generation sequencing (NGS) data, and sophisticated analytics will enable comprehensive profiling of patient immune contexture.
- “Our collaboration with BostonGene has provided in-depth information on patient phenotypes in the Phase I trial.
- “We are committed to supporting Transgene and NEC as they advance these clinical trials,” said Nathan Fowler, MD, Chief Medical Officer at BostonGene.